The Elephant Campaign taps into the psychological and physiological burden of COPD. The elephant represents the problem (breathing with COPD), and SPIRIVA represents a solution.

Itepekimab received Fast Track Designation from the U.S. Food and Drug Administration in January 2023 for the treatment of COPD in patients who do not currently smoke.

The GOLD 2023 report recognizes that triple therapy reduces mortality and exacerbations in patients with moderate-to-very-severe COPD and a prior history of exacerbations. The impact of non-pharmacological interventions on mortality, including pulmonary rehabilitation and long-term oxygen therapy, is also highlighted.

In conclusion, regular use of fluticasone propionate alone or in combination with salmeterol is associated with increased survival of chronic obstructive pulmonary disease patients managed in primary care.

New Bronchodilators and Inhaled Steroids Triple therapy, which combines a long-acting bronchodilator, an inhaled steroid, and a long-acting muscarinic antagonist (LAMA), has been shown to provide additional benefits in patients with severe COPD.

BREZTRI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Not indicated for the relief of acute bronchospasm or for the treatment of asthma. Please see full BREZTRI Prescribing Information, including Patient Information.

Oxygen therapy can improve quality of life and is the only COPD therapy proved to extend life. Talk to your doctor about your needs and options. Pulmonary rehabilitation program. These programs generally combine education, exercise training, nutrition advice and counseling.

Mesenchymal stem cells (MSCs) have shown potential in helping treat COPD (chronic obstructive pulmonary disease) by promoting the repair of damaged lung tissue. MSCs have been found to have anti-inflammatory and immunomodulatory properties, which can help alleviate airway inflammation and emphysema in COPD.

Itepekimab received Fast Track Designation from the U.S. Food and Drug Administration in January 2023 for the treatment of COPD in patients who do not currently smoke.

Many people will live into their 70s, 80s, or 90s with COPD.” But that's more likely, he says, if your case is mild and you don't have other health problems like heart disease or diabetes. Some people die earlier as a result of complications like pneumonia or respiratory failure.

TRELEGY is the only FDA-approved once-daily medicine that combines 3 long-acting medicines in 1 inhaler. TRELEGY is used to improve symptoms of COPD. TRELEGY's 3 medicines are also proven to significantly reduce flare-ups.

BREZTRI is used long term for the treatment of COPD. It can*:

• Give you better breathing.
• Improve COPD symptoms.
• Help reduce flare-ups.